Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-06-2012 | Review

Human African trypanosomiasis in endemic populations and travellers

Authors: J. A. Blum, A. L. Neumayr, C. F. Hatz

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2012

Abstract

Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b. rhodesiense (East African form) that are transmitted by the bite of the tsetse fly, Glossina spp.. Whereas most patients in endemic populations are infected with T.b. gambiense, most tourists are infected with T.b. rhodesiense. In endemic populations, T.b. gambiense HAT is characterized by chronic and intermittent fever, headache, pruritus, and lymphadenopathy in the first stage and by sleep disturbances and neuro-psychiatric disorders in the second stage. Recent descriptions of the clinical presentation of T.b. rhodesiense in endemic populations show a high variability in different foci. The symptomatology of travellers is markedly different from the usual textbook descriptions of African HAT patients. The onset of both infections is almost invariably an acute and febrile disease. Diagnosis and treatment are difficult and rely mostly on old methods and drugs. However, new molecular diagnostic technologies are under development. A promising new drug combination is currently evaluated in a phase 3 b study and further new drugs are under evaluation.

Available only for authorised users

WHO (2006) Human African trypanosomiais (sleeping sickness): epidemiological update. Weekly Epidemiological Record 8:71–80. WHO, Geneva

Simarro PP, Jannin J, Cattand P (2008) Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med 5:e55PubMedCrossRef

Robays J, Ebeja Kadima A, Lutumba P, Miaka mia Bilenge C, Kande Betu Ku Mesu V, De Deken R, Makabuza J, Deguerry M, Van der Stuyft P, Boelaert M (2004) Human African trypanosomiasis amongst urban residents in Kinshasa: a case-control study. Trop Med Int Health 9:869–875PubMedCrossRef

Bisoffi Z, Beltrame A, Monteiro G, Arzese A, Marocco S, Rorato G, Anselmi M, Viale P (2005) African trypanosomiasis gambiense, Italy. Emerg Infect Dis 11:1745–1747PubMedCrossRef

Iborra C, Danis M, Bricaire F, Caumes E (1999) A traveler returning from Central Africa with fever and a skin lesion. Clin Infect Dis 28:679–680PubMedCrossRef

Ezzedine K, Darie H, Le Bras M, Malvy D (2007) Skin features accompanying imported human African trypanosomiasis: hemolymphatic Trypanosoma gambiense infection among two French expatriates with dermatologic manifestations. J Travel Med 14:192–196PubMedCrossRef

Jelinek T, Bisoffi Z, Bonazzi L, van Thiel P, Bronner U, de Frey A, Gundersen SG, McWhinney P, Ripamonti D (2002) Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis 8:634–635PubMed

Urech K, Neumayr A, Blum J (2011) Sleeping sickness in travelers; do they really sleep? PLoS Negl Trop Dis

Mendonca MM, Rasica M, van Thiel PP, Richter C, Kager PA, Wismans PJ (2002) Three patients with African sleeping sickness following a visit to Tanzania. Ned Tijdschr Geneeskd 146:2552–2556

10.

Moore AC, Ryan ET, Waldron MA (2002) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20–2002. A 37-year-old man with fever, hepatosplenomegaly, and a cutaneous foot lesion after a trip to Africa. N Engl J Med 346:2069–2076PubMedCrossRef

11.

Moore DA, Edwards M, Escombe R, Agranoff D, Bailey JW, Squire SB, Chiodini PL (2002) African trypanosomiasis in travelers returning to the United Kingdom. Emerg Infect Dis 8:74–76PubMedCrossRef

12.

Checchi F, Filipe JA, Haydon DT, Chandramohan D, Chappuis F (2008) Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect Dis 8:16PubMedCrossRef

13.

Blum J, Schmid C, Burri C (2006) Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 97:55–64PubMedCrossRef

14.

Blum J, Burri C (2002) Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. Swiss Med Wkly 132:51–56PubMed

15.

Buguet A, Bourdon L, Bisser S, Chapotot F, Radomski MW, Dumas M (2001) Sleeping sickness: major disorders of circadian rhythm. Med Trop (Mars) 61:328–339

16.

Lundkvist GB, Kristensson K, Bentivoglio M (2004) Why trypanosomes cause sleeping sickness. Physiology (Bethesda) 19:198–206CrossRef

17.

Kennedy PG (2006) Human African trypanosomiasis—neurological aspects. J Neurol 253:411–416PubMedCrossRef

18.

Blum JA, Schmid C, Burri C, Hatz C, Olson C, Fungula B, Kazumba L, Mangoni P, Mbo F, Deo K, Mpanya A, Dala A, Franco JR, Pohlig G, Zellweger MJ (2009) Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl Trop Dis 3:e383PubMedCrossRef

19.

Blum JA, Burri C, Hatz C, Kazumba L, Mangoni P, Zellweger MJ (2007) Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis). Trop Med Int Health 12:1422–1432PubMedCrossRef

20.

Blum JA, Zellweger MJ, Burri C, Hatz C (2008) Cardiac involvement in African and American trypanosomiasis. Lancet Infect Dis 8:631–641PubMedCrossRef

21.

Collomb H, Bartoli D (1967) The heart in human African trypanosomiasis caused by Trypanosoma gambiense. Bull Soc Pathol Exot Filiales 60:142–156PubMed

22.

Poltera AA, Cox JN, Owor R (1976) Pancarditis affecting the conducting system and all valves in human African trypanosomiasis. Br Heart J 38:827–837PubMedCrossRef

23.

Poltera AA, Hochmann A, Lambert PH (1980) A model for cardiopathy induced by Trypanosoma brucei brucei in mice. A histologic and immunopathologic study. Am J Pathol 99:325–351PubMed

24.

Bertrand E, Serie F, Rive J, Compaore P, Sentilhes L, Baudin L, Renambot J, Chauvet J, Ekra A, Assamoi MO (1974) Current aspects of the cardiac symptoms in African human trypanosomiasis due to Trypanosoma gambiense (apropos of 194 cases). Acta Cardiol 29:363–381PubMed

25.

Blum JA, Schmid C, Hatz C, Kazumba L, Mangoni P, Rutishauser J, la Torre A, Burri C (2007) Sleeping glands? The role of endocrine disorders in sleeping sickness (T.b. gambiense human African trypanosomiasis). Acta Trop 104:16–24PubMedCrossRef

26.

Odiit M, Kansiime F, Enyaru JC (1997) Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. East Afr Med J 74:792–795PubMed

27.

MacLean LM, Odiit M, Chisi JE, Kennedy PG, Sternberg JM (2010) Focus-specific clinical profiles in human African trypanosomiasis caused by Trypanosoma brucei rhodesiense. PLoS Negl Trop Dis 4:e906PubMedCrossRef

28.

Boatin BA, Wyatt GB, Wurapa FK, Bulsara MK (1986) Use of symptoms and signs for diagnosis of Trypanosoma brucei rhodesiense trypanosomiasis by rural health personnel. Bull World Health Organ 64:389–395PubMed

29.

Buyst H (1977) The epidemiology of sleeping sickness in the historical Luangwa valley. Ann Soc Belg Med Trop 57:349–359PubMed

30.

Wellde BT, Chumo DA, Reardon MJ, Mwangi J, Asenti A, Mbwabi D, Abinya A, Wanyama L, Smith DH (1989) Presenting features of Rhodesian sleeping sickness patients in the Lambwe Valley, Kenya. Ann Trop Med Parasitol 83(Suppl 1):73–89PubMed

31.

Mbulamberi DB (1987) A clinical analysis of 3151 cases of Rhodesian sleeping sickness treated in the South Eastern Uganda, during the year 1985. Proceedings of the International Scientific Council for Trypanosomiasis Research and Control 19th Meeting, Lomé, Togo, pp 188–195

32.

Foulkes JR (1981) The six diseases WHO. Human trypanosomiasis in Africa. Br Med J (Clin Res Ed) 283:1172–1174CrossRef

33.

Kuepfer I, Hhary EP, Allan M, Edielu A, Burri C, Blum JA (2011) Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis 5:e968PubMedCrossRef

34.

MacLean L, Chisi JE, Odiit M, Gibson WC, Ferris V, Picozzi K, Sternberg JM (2004) Severity of human african trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun 72:7040–7044PubMedCrossRef

35.

Reincke M, Arlt W, Heppner C, Petzke F, Chrousos GP, Allolio B (1998) Neuroendocrine dysfunction in African trypanosomiasis. The role of cytokines. Ann NY Acad Sci 840:809–821PubMedCrossRef

36.

Jones IG, Lowenthal MN, Buyst H (1975) Electrocardiographic changes in African trypanosomiasis caused by Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg 69:388–395PubMedCrossRef

37.

Koten JW, De Raadt P (1969) Myocarditis in Trypanosoma rhodesiense infections. Trans R Soc Trop Med Hyg 63:485–489PubMedCrossRef

38.

Kouchner G, Bouree P, Lowenthal M (1979) Hepatic involvement in Trypanosoma rhodesiense trypanosomiasis. Bull Soc Pathol Exot Filiales 72:131–135PubMed

39.

Blum J, Beck BR, Brun R, Hatz C (2005) Clinical and serologic responses to human ‘apathogenic’ trypanosomes. Trans R Soc Trop Med Hyg 99:795–797PubMedCrossRef

40.

Jamonneau V, Ravel S, Garcia A, Koffi M, Truc P, Laveissiere C, Herder S, Grebaut P, Cuny G, Solano P (2004) Characterization of Trypanosoma brucei s.l. infecting asymptomatic sleeping-sickness patients in Cote d'Ivoire: a new genetic group? Ann Trop Med Parasitol 98:329–337PubMedCrossRef

41.

Duggan AJ, Hutchinson MP (1966) Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg 69:124–131PubMed

42.

Sinha A, Grace C, Alston WK, Westenfeld F, Maguire JH (1999) African trypanosomiasis in two travelers from the United States. Clin Infect Dis 29:840–844PubMedCrossRef

43.

Apted FJ, Smyly DP, Ormero WE, Stronach BW (1963) A comparative study of the epidemiology of endemic Rhodesian sleeping sickness in different parts of Africa. J Trop Med Hyg 66:1–16PubMed

44.

Ripamonti D, Massari M, Arici C, Gabbi E, Farina C, Brini M, Capatti C, Suter F (2002) African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. Clin Infect Dis 34:E18–E22PubMedCrossRef

45.

Braendli B, Dankwa E, Junghanss T (1990) East African sleeping sickness (Trypanosoma rhodesiense infection) in 2 Swiss travelers to the tropics. Schweiz Med Wochenschr 120:1348–1352PubMed

46.

Sanner BM, Doberauer C, Tepel M, Zidek W (2000) Fulminant disease simulating bacterial sepsis with disseminated intravascular coagulation after a trip to East Africa. Intensive Care Med 26:646–647PubMedCrossRef

47.

Oscherwitz SL (2003) East African trypanosomiasis. J Travel Med 10:141–143PubMedCrossRef

48.

Quinn TC, Hill CD (1983) African trypanosomiasis in an American hunter in East Africa. Arch Intern Med 143:1021–1023PubMedCrossRef

49.

Croft AM, Jackson CJ, Friend HM, Minton EJ (2006) African trypanosomiasis in a British soldier. J R Army Med Corps 152:156–160PubMed

50.

Damian MS, Dorndorf W, Burkardt H, Singer I, Leinweber B, Schachenmayr W (1994) Polyneuritis and myositis in Trypanosoma gambiense infection. Dtsch Med Wochenschr 119:1690–1693PubMedCrossRef

51.

Chappuis F, Loutan L, Simarro P, Lejon V, Buscher P (2005) Options for field diagnosis of human african trypanosomiasis. Clin Microbiol Rev 18:133–146PubMedCrossRef

52.

Camara M, Camara O, Ilboudo H, Sakande H, Kabore J, N'Dri L, Jamonneau V, Bucheton B (2010) Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test. Trop Med Int Health 15:796–799PubMedCrossRef

53.

Deborggraeve S, Lejon V, Ekangu RA, Mumba ND, Pati PP, Ilunga M, Mulunda JP, Buscher P (2011) Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study. PLoS Negl Trop Dis 5:e972PubMedCrossRef

54.

WHO (1998) Control and surveillance of African trypanosomiasis. WHO Technical report, WHO, Geneva

55.

Lejon V, Robays J, N'Siesi FX, Mumba D, Hoogstoel A, Bisser S, Reiber H, Boelaert M, Buscher P (2007) Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness. Clin Vaccine Immunol 14:732–737PubMedCrossRef

56.

Lejon V, Buscher P (2005) Review article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Int Health 10:395–403PubMedCrossRef

57.

Kennedy PG (2010) Novel biomarkers for late-stage human African trypanosomiasis—the search goes on. Am J Trop Med Hyg 82:981–982PubMedCrossRef

58.

Hainard A, Tiberti N, Robin X, Lejon V, Ngoyi DM, Matovu E, Enyaru JC, Fouda C, Ndung'u JM, Lisacek F, Muller M, Turck N, Sanchez JC (2009) A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis 3:e459PubMedCrossRef

59.

Amin DN, Ngoyi DM, Nhkwachi GM, Palomba M, Rottenberg M, Buscher P, Kristensson K, Masocha W (2010) Identification of stage biomarkers for human African trypanosomiasis. Am J Trop Med Hyg 82:983–990PubMedCrossRef

60.

Mumba ND, Lejon V, N'Siesi FX, Boelaert M, Buscher P (2009) Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis. Trop Med Int Health 14:438–444CrossRef

61.

Mumba ND, Lejon V, Pyana P, Boelaert M, Ilunga M, Menten J, Mulunda JP, Van Nieuwenhove S, Muyembe Tamfum JJ, Buscher P (2010) How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 201:453–463CrossRef

62.

Deborggraeve S, Buscher P (2010) Molecular diagnostics for sleeping sickness: what is the benefit for the patient? Lancet Infect Dis 10:433–439PubMedCrossRef

63.

Becker S, Franco JR, Simarro PP, Stich A, Abel PM, Steverding D (2004) Real-time PCR for detection of Trypanosoma brucei in human blood samples. Diagn Microbiol Infect Dis 50:193–199PubMedCrossRef

64.

Truc P, Lejon V, Magnus E, Jamonneau V, Nangouma A, Verloo D, Penchenier L, Buscher P (2002) Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa. Bull World Health Organ 80:882–886PubMed

65.

Louis FJ, Buscher P, Lejon V (2001) Diagnosis of human African trypanosomiasis in 2001. Med Trop (Mars) 61:340–346

66.

Bisser S, Bouteille B, Sarda J, Stanghellini A, Ricard D, Jauberteau MO, Marchan F, Dumas M, Breton JC (1997) Contribution of biochemical tests in the diagnosis of the nervous phase of human African trypanosomiasis. Bull Soc Pathol Exot 90:321–326PubMed

67.

Sabbah P, Brosset C, Imbert P, Bonardel G, Jeandel P, Briant JF (1997) Human African trypanosomiasis: MRI. Neuroradiology 39:708–710PubMedCrossRef

68.

Gill DS, Chatha DS, Carpio-O'Donovan R (2003) MR imaging findings in African trypansomiasis. AJNR Am J Neuroradiol 24:1383–1385PubMed

69.

Braakman HM, van de Molengraft FJ, Hubert WW, Boerman DH (2006) Lethal African trypanosomiasis in a traveler: MRI and neuropathology. Neurology 66:1094–1096PubMedCrossRef

70.

Serrano-Gonzalez C, Velilla I, Fortuno B, Guelbenzu S, Portoles A (1996) Neuroimaging and efficacy of treatment in advanced African trypanosomiasis. Rev Neurol 24:1554–1557PubMed

71.

Bedat-Millet AL, Charpentier S, Monge-Strauss MF, Woimant F (2000) Psychiatric presentation of human African trypanosomiasis: overview of diagnostic pitfalls, interest of difluoromethylornithine treatment and contribution of magnetic resonance imaging. Rev Neurol (Paris) 156:505–509

72.

Dorlo TP, Kager PA (2008) Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis 2:e225PubMedCrossRef

73.

Blum JA, Hatz CF (2009) Treatment of cutaneous leishmaniasis in travelers. J Travel Med 16:123–131PubMedCrossRef

74.

Burri C (2010) Chemotherapy against human African trypanosomiasis: Is there a road to success? Parasitology 137:1987–1994PubMedCrossRef

75.

Blum J, Nkunku S, Burri C (2001) Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6:390–400PubMedCrossRef

76.

Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, Checchi F (2009) Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc Trop Med Hyg 103:280–290PubMedCrossRef

77.

Robays J, Nyamowala G, Sese C, Betu Ku MKV, Lutumba P, Van der V, Boelaert M (2008) High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 14:966–967PubMedCrossRef

78.

Seixas J (2004) Investigations of the encephalopathic syndrome during melarsoprol treatment of human African trypanosomiasis. Dissertation, The Swiss Tropicla and Health Institute, Switzerland and the Universidade Nova de Lisboa, Portugal

79.

Pepin J, Milord F, Khonde AN, Niyonsenga T, Loko L, Mpia B, De Wals P (1995) Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 89:92–97PubMedCrossRef

80.

Pepin J, Tetreault L, Gervais C (1985) The use of oral corticosteroids in the treatment of human African trypanosomiasis: a retrospective survey in Nioki, Zaire. Ann Soc Belg Med Trop 65:17–29PubMed

81.

Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355:1419–1425PubMedCrossRef

82.

Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, Nangouma A, Doua F, Asumu PN, Simarro PP, Burri C (2005) Effectiveness of a 10-day Melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (Impamel II). J Infect Dis 191:1922–1931PubMedCrossRef

83.

Pepin J, Mpia B (2006) Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Trans R Soc Trop Med Hyg 100:437–441PubMedCrossRef

84.

Burri C, Blum J, Brun R (1995) Alternative application of melarsoprol for treatment of T.B. gambiense sleeping sickness. Preliminary results. Ann Soc Belg Med Trop 75:65–71PubMed

85.

Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA (2005) Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 41:748–751PubMedCrossRef

86.

Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D, L-alpha-difluoromethylornithine. Antimicrob Agents Chemother 41:1922–1925PubMed

87.

Burri C, Brun R (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 90(Supp 1):S49–S52PubMed

88.

Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U (2007) Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 45:1435–1442PubMedCrossRef

89.

Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, Hewison C, Balasegaram M (2008) Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 336:705–708PubMedCrossRef

90.

Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374:56–64PubMedCrossRef

91.

Schmid C, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Tete D, Nganzobo P, Mubwa N, Blum J, Balasegaram M, Valverde O (2010) NECT-FIELD: Clinical trial to evaluate the tolerability, feasibility, and effectiveness of NECT treatment in "real-life" conditions for late stage sleeping sickness. LB-2253, Annual Meeting, American Society of Tropiclal Medicine and Hygine, Poster Session C Presentations, 31-1-2010

92.

Adams JH, Haller L, Boa FY, Doua F, Dago A, Konian K (1986) Human African trypanosomiasis (T.b. gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy. Neuropathol Appl Neurobiol 12:81–94PubMedCrossRef

93.

Haller L, Adams H, Merouze F, Dago A (1986) Clinical and pathological aspects of human African trypanosomiasis (T.b. gambiense) with particular reference to reactive arsenical encephalopathy. Am J Trop Med Hyg 35:94–99PubMed

94.

Pepin J, Milord F (1991) African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis. Trans R Soc Trop Med Hyg 85:222–224PubMedCrossRef

95.

Le Bras J, Sina G, Triolo N, Trova P (1977) Symptomatology générale de la trypanosomiase humaine africaine de l'enfant. Med Trop (Mars) 37:51–61

96.

Boa YF, Traore MA, Doua F, Kouassi-Traore MT, Kouassi BE, Giordano C (1988) The different present-day clinical picture of human African trypanosomiasis caused by T.b. gambiense. Analysis of 300 cases from a focus in Daloa, Ivory Coast. Bull Soc Pathol Exot Filiales 81:427–444PubMed

97.

Bertrand E, Serie F, Kone I, Rive J, Campaore P, Sentilhes L, Philippe J (1973) Symptomatologie générale de la trypanosomiase humaine africaine au moment du dépistage. Médecine d'Afrique Noire 20:303–314

98.

Debroise A, Debroise-Ballereau C, Satge P, Rey M (1968) African trypanosomiasis in young children. Arch Fr Pediatr 25:703–720PubMed

99.

Ngandu-Kabeya G (1976) Study of the symptomatology of African trypanosomiasis in children (apropos of 24 cases). Ann Soc Belg Med Trop 56:85–93PubMed

100.

Edan G (1979) Clinical and biological symptoms of T. gambiense tryponosomiasis in the meningo-encephalitic period (author's transl). Med Trop (Mars) 39:499–507

101.

Ginoux PY, Frezil JL, Alary JC (1982) Symptoms of human trypanosomiasis at the first diagnostic phase in the People Republic of Congo (author's transl). Med Trop (Mars) 42:281–287

102.

Antoine P (1977) Neurological and psychological studies of patients with sleeping sickness and their course. Ann Soc Belg Med Trop 57:227–248PubMed

Title: Human African trypanosomiasis in endemic populations and travellers
Authors: J. A. Blum
A. L. Neumayr
C. F. Hatz
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-011-1403-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

The effect of a whole-system approach in an antimicrobial stewardship programme at the Singapore General Hospital

Seroprevalence for toxoplasmosis in individuals living in North West Tuscany: access to Toxo-test in central Italy

Comparison of ELISA and indirect immunofluorescent antibody assay detecting Coxiella burnetii IgM phase II for the diagnosis of acute Q fever

Prevalence of nasal methicillin-resistant Staphylococcus aureus colonization in healthcare workers in a Western Australian acute care hospital

The first detection of Toxoplasma gondii DNA in environmental fruits and vegetables samples

Detection of three human adenovirus species in adults with acute respiratory infection in China

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials